Literature DB >> 22110843

Variant angina pectoris associated with FOLFOX4 therapy.

Hiromichi Yamane1, Minoru Matsubara, Shigeki Umemura, Toshimitsu Suwaki, Haruhito Kamei, Nagio Takigawa, Katsuyuki Kiura, Mitsune Tanimoto.   

Abstract

The patient was a 71-year-old man who underwent a right hemicolectomy for ascending colon cancer (pT3, pN1, pM0) and who opted not to receive adjuvant chemotherapy. Eight months later, multiple liver metastases occurred. He therefore received FOLFOX4 (5-fluorouracil/leucovorin and 85 mg/m(2) oxaliplatin) therapy, up to a total of 5 courses, and showed a partial response. While receiving the sixth course of FOLFOX4, he complained of chest pain and systemic itching approximately 15 min after the start of chemotherapy. An electrocardiogram revealed typical signs of ischemia. Coronary arteriography showed that the coronary arteries were intact. Believing the chest pain to be merely coincidental, we continued with the same therapy. However, he again developed the same chest pain during the seventh cycle of FOLFOX4 and treatment was stopped. We concluded that the patient's symptoms were due to acute coronary syndrome (ACS) associated with the FOLFOX4 regimen. Variant angina as a type of ACS is a rare adverse effect of FOLFOX4. Clinicians should be aware of this potential adverse effect when monitoring patients receiving FOLFOX4.

Entities:  

Keywords:  Acute coronary syndrome; Allergy; FOLFOX4; Variant angina

Year:  2011        PMID: 22110843      PMCID: PMC3220725          DOI: 10.4251/wjgo.v3.i11.165

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  19 in total

1.  Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.

Authors:  Frédérique Maindrault-Goebel; Thierry André; Christophe Tournigand; Christophe Louvet; Nathalie Perez-Staub; Nora Zeghib; Aimery De Gramont
Journal:  Eur J Cancer       Date:  2005-09-09       Impact factor: 9.162

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

3.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

4.  Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Authors:  Fairooz F Kabbinavar; Joseph Schulz; Michael McCleod; Taral Patel; John T Hamm; J Randolph Hecht; Robert Mass; Brent Perrou; Betty Nelson; William F Novotny
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

5.  Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?

Authors:  David Pereg; Michael Lishner
Journal:  Eur Heart J       Date:  2008-09-01       Impact factor: 29.983

6.  In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle.

Authors:  M Mosseri; H J Fingert; L Varticovski; S Chokshi; J M Isner
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

7.  Endothelin-1 and 5-fluorouracil-induced cardiotoxicity.

Authors:  C Porta; M Moroni; S Ferrari; G Nastasi
Journal:  Neoplasma       Date:  1998       Impact factor: 2.575

8.  [Adjuvant treatment of colon cancer MOSAIC study's main results].

Authors:  Thierry André; Christophe Tournigand; Emmanuel Achille; Nicole Tubiana-Mathieu; Gérard Lledo; Yves Raoul; Elisabeth Carola; Michel Flesch; Thierry Muron; Arnaud Boutan-Laroze; Véronique Guérin Meyer; Catherine Boaziz; Michel Maigre; Gérard Ganem; Mireille Mousseau; Lamia Mounedji-Boudiaf; Aimery de Gramont
Journal:  Bull Cancer       Date:  2006-02-01       Impact factor: 1.276

9.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

Review 10.  Oxaliplatin-safety profile: neurotoxicity.

Authors:  Axel Grothey
Journal:  Semin Oncol       Date:  2003-08       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.